No popular authors found.

Categories

No categories found.


Join Celiac.com's forum / message board and get your questions answered! Our forum has nearly 1 MILLION POSTS, and over 62,000 MEMBERS just waiting to help you with any questions about celiac disease and the gluten-free diet. We'll see you there!






Follow / Share


  FOLLOW US:
Twitter Facebook Google Plus RSS Podcast Email  Get Email Alerts

SHARE:

Popular Articles

No popular articles found.
Celiac.com Sponsors:

Cladribine Treatment Promising for Type II Refractory Celiac Disease


New study on cladribine treatment for Type II Refractory celiac disease.

Celiac.com 03/25/2011 - A group of researchers recently set out to evaluate cladribine [2-chlorodeoxyadenosine (2-CdA)] therapy in refractory celiac disease (RCD) Ⅱ.

The team included Greetje J. Tack, Wieke H. M. Verbeek, Abdul Al-Toma, Dirk J. Kuik, Marco W. J. Schreurs, Otto Visser, Chris J. J. Mulder of the Department of Gastroenterology and Hepatology,  at VU University Medical Center, Amsterdam, The Netherlands.

Between 2000 and 2010, the research team conducted an open-label cohort-study of RCD Ⅱ patients treated with 2-CdA. They assessed survival rate, enteropathy associated T-cell lymphoma (EATL) occurrence, clinical course, and histological and immunological response rates.

The study followed a total of  32 patients over an average 31-month period. Eighteen patients responded well to 2-CdA. Patients responsive to 2-CdA showed markedly higher survival rates, compared to unresponsive patients.

The responder group showed an 83% survival rate at the 3- and 5-year mark, compared to rates of 63% and 22% in the non-responder group. The responder group showed an 81% clinical, histological and immunological response rates at the 2-year mark, compared to rates of 47% and 41% in the non-responder group. 16% of non-responsive patients progressed into EATL, and all of these patients died.

Because 2-CdA shows excellent clinical and histological response rates, and probably less frequent transition into EATL, it looks like a promising treatment for RCD II.

Source:

Celiac.com welcomes your comments below (registration is NOT required).



Related Articles




Spread The Word





4 Responses:

 
Clayton Secord
Rating: ratingfullratingfullratingfullratingfullratingempty Unrated
said this on
28 Mar 2011 9:03:21 AM PST
Good article, but you do not mention anything about the accomplishments of Sidney Australia. They have develop some vaccination for celiac spruce disease.

 
Fernando A. Garza
Rating: ratingfullratingfullratingfullratingemptyratingempty Unrated
said this on
01 Apr 2011 7:41:34 AM PST
I am not sure what the article is about. Who is type II.

 
Clayton Secord
Rating: ratingfullratingfullratingfullratingfullratingfull Unrated
said this on
25 Jan 2014 4:24:55 PM PST
Very nice article about celiac spruce and lymphomas.

 
Clayton Secord

said this on
25 Jan 2014 4:31:44 PM PST
The article is good, but why did it not mention how some physicians argue that it is a mass with possible "carcinoid" which is not true.




Rate this article and leave a comment:
Rating: * Poor Excellent
Your Name *: Email (private) *: